drugset / Trial / NCT00806481
Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease
Phase 2
Completed
120 enrolled
University Hospital Birmingham NHS Foundation Trust
Genzyme, a Sanofi Company · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to determine whether lowering phosphate in patients with early chronic kidney disease with the phosphate binder sevelamer has beneficial effects on cardiovascular structure and function.
Timeline
- Start
- 2009-02
- Primary completion
- 2011-10
- Completion
- 2011-10
Publications
- Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
- Chue CD, Townend JN, Steeds RP, Ferro CJ. Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. Trials. 2011 Feb 2;12:30. doi: 10.1186/1745-6215-12-30.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sevelamer | Other / unclassified | 1600 mg | — |